PL2136795T3 - Systemy transdermalne amorficznego leku, sposoby wytwarzania i stabilizowanie - Google Patents

Systemy transdermalne amorficznego leku, sposoby wytwarzania i stabilizowanie

Info

Publication number
PL2136795T3
PL2136795T3 PL08726714T PL08726714T PL2136795T3 PL 2136795 T3 PL2136795 T3 PL 2136795T3 PL 08726714 T PL08726714 T PL 08726714T PL 08726714 T PL08726714 T PL 08726714T PL 2136795 T3 PL2136795 T3 PL 2136795T3
Authority
PL
Poland
Prior art keywords
stabilization
manufacturing methods
transdermal systems
amorphous drug
drug transdermal
Prior art date
Application number
PL08726714T
Other languages
English (en)
Inventor
Jiansheng Tang
Joseph M Deverich
Kenneth J Ii Miller
Russell D Beste
Original Assignee
Mylan Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39530666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2136795(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mylan Tech Inc filed Critical Mylan Tech Inc
Publication of PL2136795T3 publication Critical patent/PL2136795T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08726714T 2007-03-16 2008-03-11 Systemy transdermalne amorficznego leku, sposoby wytwarzania i stabilizowanie PL2136795T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/725,159 US20080226698A1 (en) 2007-03-16 2007-03-16 Amorphous drug transdermal systems, manufacturing methods, and stabilization
PCT/US2008/003221 WO2008115371A2 (en) 2007-03-16 2008-03-11 Amorphous drug transdermal systems, manufacturing methods, and stabilization
EP08726714.2A EP2136795B1 (en) 2007-03-16 2008-03-11 Amorphous drug transdermal systems, manufacturing methods, and stabilization

Publications (1)

Publication Number Publication Date
PL2136795T3 true PL2136795T3 (pl) 2014-02-28

Family

ID=39530666

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08726714T PL2136795T3 (pl) 2007-03-16 2008-03-11 Systemy transdermalne amorficznego leku, sposoby wytwarzania i stabilizowanie

Country Status (15)

Country Link
US (1) US20080226698A1 (pl)
EP (3) EP2522339A3 (pl)
JP (2) JP2010521525A (pl)
KR (2) KR101488457B1 (pl)
CN (2) CN106074455A (pl)
AU (1) AU2008227090B2 (pl)
BR (1) BRPI0808864A2 (pl)
CA (3) CA2679535C (pl)
ES (1) ES2436290T3 (pl)
HK (1) HK1134434A1 (pl)
MX (1) MX2009009856A (pl)
NZ (1) NZ580443A (pl)
PL (1) PL2136795T3 (pl)
PT (1) PT2136795E (pl)
WO (1) WO2008115371A2 (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017301B2 (en) 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
EP2259780A2 (en) * 2008-02-28 2010-12-15 Syntropharma Limited Pharmaceutical composition comprising naltrexone
PL2285924T3 (pl) * 2008-04-22 2014-11-28 3M Innovative Properties Co Artykuł przylepny
DE102008021842A1 (de) * 2008-04-30 2009-11-05 Tesa Se Polyolefinfolie und Verwendung derselben
JP5695562B2 (ja) * 2008-05-30 2015-04-08 マイラン・インコーポレーテッド 安定化された経皮薬物送達システム
EP2349230A2 (en) * 2008-10-06 2011-08-03 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
JP2010163367A (ja) * 2009-01-13 2010-07-29 Nitto Denko Corp 貼付剤および貼付製剤
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
DE102009052972A1 (de) * 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
AU2010334805B2 (en) 2009-12-22 2015-01-22 Lts Lohmann Therapie-Systeme Ag Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
JP5766475B2 (ja) * 2010-03-30 2015-08-19 日東電工株式会社 貼付製剤およびその製造方法
US8563031B2 (en) * 2010-05-27 2013-10-22 Absize, Inc. Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
CN102038664A (zh) * 2010-12-20 2011-05-04 蚌埠丰原涂山制药有限公司 一种东莨菪碱透皮贴片及其制备方法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX365818B (es) 2011-11-23 2019-05-30 Therapeuticsmd Inc Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
KR101558043B1 (ko) * 2012-07-06 2015-10-07 에스케이케미칼주식회사 로티고틴 함유 경피흡수제제
JP5270035B1 (ja) * 2012-12-06 2013-08-21 久光製薬株式会社 貼付剤及びその製造方法
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP5307931B1 (ja) * 2012-12-27 2013-10-02 久光製薬株式会社 貼付剤及びその製造方法
CN103919755B (zh) * 2013-01-15 2019-10-18 江苏康倍得药业股份有限公司 妥洛特罗透皮贴剂及其制备方法
JP5415645B1 (ja) 2013-06-28 2014-02-12 久光製薬株式会社 貼付剤の製造方法、貼付剤及び包装体
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN104208041B (zh) * 2014-08-28 2018-12-21 上海赛琅医药科技有限公司 一种用于预防、干预疤痕以及疤痕增生的可塑性硅凝胶和其制作方法
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
CN107406554B (zh) * 2015-02-09 2023-04-14 美国陶氏有机硅公司 多相有机硅丙烯酸类混杂粘弹性组合物及其制备方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2018031043A1 (en) * 2016-08-12 2018-02-15 North Carolina State University Surface-modified polymers
WO2018070370A1 (ja) * 2016-10-11 2018-04-19 久光製薬株式会社 オキシブチニン含有経皮吸収製剤
AU2017384392B2 (en) 2016-12-20 2023-05-25 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
RU2762896C2 (ru) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин
TW201946617A (zh) 2017-04-28 2019-12-16 日商日東電工股份有限公司 經皮吸收製劑
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
CN107320463A (zh) * 2017-07-10 2017-11-07 徐静 一种含有单硝酸异山梨酯的缓释透皮贴剂及其应用
BR112020003314A2 (pt) * 2017-09-04 2020-08-25 Lts Lohmann Therapie-Systeme Ag sistema de liberação transdérmico incluindo um emulsificante
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
JP7307731B2 (ja) * 2018-01-03 2023-07-12 コロプラスト アクティーゼルスカブ ストーマ周囲領域用スキンケア組成物
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CA3118746A1 (en) 2018-11-09 2020-05-14 Sofresh, Inc. Blown film materials and processes for manufacturing thereof and uses thereof
GB2588612A (en) * 2019-10-28 2021-05-05 Univ Of Sunderland Transdermal patch
CN112891324A (zh) * 2021-01-19 2021-06-04 北京亚宝生物药业有限公司 一种透皮贴剂

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US516419A (en) * 1894-03-13 Means for the propulsion of vessels
US4022203A (en) * 1976-01-22 1977-05-10 Win Ackley Treated patch for minor cuts
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
DE3204551A1 (de) * 1982-02-10 1983-08-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung einer pharmazeutischen zubereitung in form eines polyacrylat-films
US4655767A (en) * 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4880633A (en) * 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
JPH066534B2 (ja) * 1986-10-09 1994-01-26 積水化学工業株式会社 経皮吸収貼付剤
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US4814168A (en) * 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
JP2820306B2 (ja) * 1990-02-27 1998-11-05 積水化学工業株式会社 経皮吸収製剤
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5164190A (en) 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US6162456A (en) * 1992-09-24 2000-12-19 Ortho-Mcneil Pharmaceutical, Inc. Adhesive transdermal drug delivery matrix of a physical blend of hydrophilic and hydrophobic polymers
US5662928A (en) * 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US6238700B1 (en) * 1995-12-01 2001-05-29 Alza Corporation Method for preventing crystal formation in a dispersion of a liquid in a matrix
EP0863751B1 (en) * 1995-12-01 2001-10-24 Alza Corporation Improved method for preventing crystal formation in a dispersion of a liquid in a matrix
DE19548332A1 (de) * 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
US6623763B2 (en) * 1996-01-08 2003-09-23 Lts Lohmann Therape-System Ag Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism
US5869089A (en) * 1996-03-21 1999-02-09 China-America Technology Corp. (Ctc) Manufacturing method of programmable transdermal therapeutic system
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
AU1728099A (en) * 1997-12-22 1999-07-12 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
SE9801704D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
US6337086B1 (en) * 1999-02-06 2002-01-08 Dow Corning Corporation Pressure sensitive adhesive compositions for transdermal drug delivery devices
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20020106402A1 (en) * 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
DE10212864B4 (de) * 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
JP4792193B2 (ja) * 2002-08-28 2011-10-12 久光製薬株式会社 貼付剤
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
EP2316437B1 (en) * 2005-05-13 2014-07-30 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow

Also Published As

Publication number Publication date
EP2136795B1 (en) 2013-09-04
WO2008115371A2 (en) 2008-09-25
US20080226698A1 (en) 2008-09-18
CN101674816A (zh) 2010-03-17
CA2762981C (en) 2016-11-29
KR20090120498A (ko) 2009-11-24
CN106074455A (zh) 2016-11-09
CA2679535C (en) 2014-09-09
EP2522339A2 (en) 2012-11-14
AU2008227090A1 (en) 2008-09-25
JP6068324B2 (ja) 2017-01-25
PT2136795E (pt) 2013-11-19
CA2679535A1 (en) 2008-09-25
KR101488458B1 (ko) 2015-01-30
JP2010521525A (ja) 2010-06-24
WO2008115371A3 (en) 2009-08-27
BRPI0808864A2 (pt) 2014-09-23
EP2848248A2 (en) 2015-03-18
JP2014065727A (ja) 2014-04-17
CA2947796A1 (en) 2008-09-25
ES2436290T3 (es) 2013-12-30
EP2848248A3 (en) 2015-03-25
AU2008227090B2 (en) 2014-05-08
CN101674816B (zh) 2016-10-26
EP2136795A2 (en) 2009-12-30
HK1134434A1 (en) 2010-04-30
MX2009009856A (es) 2009-12-14
NZ580443A (en) 2012-07-27
CA2762981A1 (en) 2008-09-25
EP2522339A3 (en) 2014-01-22
KR101488457B1 (ko) 2015-02-02
KR20130030308A (ko) 2013-03-26

Similar Documents

Publication Publication Date Title
HK1134434A1 (en) Amorphous drug transdermal systems, manufacturing methods, and stabilization
EP2249909A4 (en) CATHETER DEVICES WITH GUIDING COMMITMENT, SYSTEMS AND METHODS
EP2355699A4 (en) MEDICAL DEVICES, DEVICES, SYSTEMS AND METHOD
EP2111173A4 (en) TREATMENT SYSTEM AND TREATMENT DEVICE
IL209985A0 (en) Systems, apparatuses, and methods for providing non-transcranial electrotherapy
EP2251050A4 (en) DRUG ELUTING TYPE CATHETER AND METHOD FOR MANUFACTURING THE DRUG ELUTING TYPE CATHETER
EP2433215A4 (en) SYSTEMS AND METHODS FOR IMPLEMENTING APPLICATION-LEVEL SECURITY
EP2349140A4 (en) DEVICES, SYSTEMS AND METHODS FOR TREATING SLEEP APNEA
SG10201606508VA (en) Patient-specific bin systems, methods and devices
HK1144375A1 (en) Transdermal delivery system
IL201578A0 (en) Methods, devices, and systems useful in registration
EP2187957A4 (en) SELECTIVE CYTOPHERESIS DEVICES AND CORRESPONDING METHODS
ZA200906118B (en) Descenting systems and methods
IL200077A0 (en) Transdermal delivery systems
IL210447A0 (en) Icotinib hydrochloride, synthesis, crystalline forms, drug combinations, and uses thereof
EP2293095A4 (en) METHOD, SYSTEM AND DEVICES FOR RADIO TRACKING
EP2244642A4 (en) SYSTEMS, APPARATUS AND METHOD FOR ACCESSING BODY TISSUE
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
EP2153633A4 (en) METHOD FOR MONITORING WIRELESS DEVICES, SYSTEMS FOR MONITORING WIRELESS DEVICES AND MANUFACTURED ITEMS
PL2140090T3 (pl) Urządzenia ograniczające
EP2504938A4 (en) Methods, systems and devices for providing fiber-to-the-desktop
EP2247528A4 (en) NANOBAUTEIL, NANOBAUTEIL COMPRISING TRANSISTOR, METHOD FOR PRODUCING NANOBAUTEILS AND METHOD FOR PRODUCING TRANSISTORS
EP2306889A4 (en) OPHTHALMIC APPARATUS, SYSTEMS AND METHODS
EP2172374A4 (en) TAB AND MANUFACTURING METHOD THEREOF
EP2281243A4 (en) DEFINITION, DISTRIBUTION AND PRESENTATION OF DEVICE EXPERIENCES